Article Sidebar
Main Article Content
Abstract
Symmetric dimethylarginine (SDMA), is a post-translationally stable catabolic product of arginine-methylated proteins that plays an important role in basic cellular metabolism. SDMA is an endogenous biomarker of kidney function that has been widely used in veterinary medicine. Symmetric dimethylarginine (SDMA) and asymmetric dimethylarginine (ADMA) are 2 constant products of L-arginine proteolysis that undergo methylation. SDMA is almost completely excreted by the kidneys after filtration making SDMA an ideal GFR biomarker candidate. Apart from that, SDMA has several advantages as a biomarker of kidney function, namely that it is not affected by non-renal factors that influence creatinine and cystatin C. Apart from that, SDMA also increases earlier than other biomarkers.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
